和黄医药(00013)将于2025年欧洲肿瘤内科学会 (ESMO) 年会公布临床数据

智通财经
Oct 02

智通财经APP讯,和黄医药(00013)发布公告,该公司今日宣布将于2025年10月17日至21日在德国柏林召开的欧洲肿瘤内科学会2025年年会上公布和黄医药自主研发的化合物的数项研究的最新及更新后的数据。

呋喹替尼(fruquintinib)联合信迪利单抗(sintilimab)用于二线治疗局部晚期或转移性肾细胞癌的FRUSICA-2注册研究结果将于迷你口头报告环节公布。此外,呋喹替尼用于治疗子宫内膜癌的FRUSICA-1研究,以及赛沃替尼 ( savolitinib)用于治疗非小细胞肺癌的SACHI和SAVANNAH研究的进一步分析结果将于海报展示环节公布。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10